Novo real‑world studies show Wegovy 2.4 mg cuts weight and liver enzymes in MASH patients
Novo Nordisk presented two retrospective analyses of adults with metabolic dysfunction‑associated steatohepatitis (MASH). In the PLATINUM‑Truveta cohort, semaglutide 2.4 mg produced a mean 18.9‑lb (8.6 kg) weight loss and larger reductions in AST and ALT over six months versus resmetirom. The RHODIUM‑2 analysis showed a 30.7‑lb weight loss and greater ALT and AST declines after 12 months compared with patients who did not start semaglutide. The company said the findings give clinicians real‑world insight into managing MASH.
Why it matters
Novo says the data support Wegovy’s benefit for MASH, which could broaden its use beyond obesity and diabetes and strengthen demand for the product. Investors may see a positive impact on Novo’s pipeline perception and future sales forecasts.
Key facts
- 1PLATINUM‑Truveta included 2,873 adults who started semaglutide 2.4 mg and 2,285 adults who started resmetirom. prnewswire.com
- 2At six months, semaglutide users lost an adjusted mean of 18.9 lb (8.6 kg) versus a 5.6‑lb loss for resmetirom users. prnewswire.com
- 3At six months, semaglutide reduced AST by 10.4 U/L compared with a 4.5 U/L reduction for resmetirom (P < 0.001). prnewswire.com
- 4At six months, semaglutide reduced ALT by 14.8 U/L versus 11.6 U/L for resmetirom (P = 0.20). prnewswire.com
- 5RHODIUM‑2 compared 2,479 semaglutide initiators with 70,702 non‑initiators. prnewswire.com
- 6After 12 months, semaglutide users lost an adjusted mean of 30.7 lb versus 2.4 lb for non‑initiators (between‑group difference = ‑28.4 lb, P < 0.001). prnewswire.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.